ATE154641T1 - Neues physiologisch aktives schweinepeptid (cnp- 53) - Google Patents

Neues physiologisch aktives schweinepeptid (cnp- 53)

Info

Publication number
ATE154641T1
ATE154641T1 AT91111629T AT91111629T ATE154641T1 AT E154641 T1 ATE154641 T1 AT E154641T1 AT 91111629 T AT91111629 T AT 91111629T AT 91111629 T AT91111629 T AT 91111629T AT E154641 T1 ATE154641 T1 AT E154641T1
Authority
AT
Austria
Prior art keywords
peptide
cnp
swine
physiologically active
new physiologically
Prior art date
Application number
AT91111629T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Original Assignee
Hisayuki Matsuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisayuki Matsuo filed Critical Hisayuki Matsuo
Application granted granted Critical
Publication of ATE154641T1 publication Critical patent/ATE154641T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91111629T 1990-07-13 1991-07-12 Neues physiologisch aktives schweinepeptid (cnp- 53) ATE154641T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2186582A JP2930380B2 (ja) 1990-07-13 1990-07-13 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）

Publications (1)

Publication Number Publication Date
ATE154641T1 true ATE154641T1 (de) 1997-07-15

Family

ID=16191066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91111629T ATE154641T1 (de) 1990-07-13 1991-07-12 Neues physiologisch aktives schweinepeptid (cnp- 53)

Country Status (8)

Country Link
US (1) US5340920A (de)
EP (1) EP0466174B1 (de)
JP (1) JP2930380B2 (de)
AT (1) ATE154641T1 (de)
DE (1) DE69126568T2 (de)
DK (1) DK0466174T3 (de)
ES (1) ES2104635T3 (de)
GR (1) GR3024581T3 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2345414A1 (en) * 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Eyedrops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as active ingredient
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4825667B2 (ja) 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
EP3620530A1 (de) 2004-03-31 2020-03-11 Kazuwa Nakao Zusammensetzung zur erhöhung der körpergrösse
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
AU2008326327A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
PE20120792A1 (es) 2009-05-20 2012-07-27 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3337894A1 (de) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Herstellung von alkalischen phosphatasen
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DK0466174T3 (da) 1998-01-12
EP0466174B1 (de) 1997-06-18
GR3024581T3 (en) 1997-12-31
JPH0474198A (ja) 1992-03-09
DE69126568D1 (de) 1997-07-24
JP2930380B2 (ja) 1999-08-03
ES2104635T3 (es) 1997-10-16
EP0466174A1 (de) 1992-01-15
US5340920A (en) 1994-08-23
DE69126568T2 (de) 1997-11-27

Similar Documents

Publication Publication Date Title
ATE154641T1 (de) Neues physiologisch aktives schweinepeptid (cnp- 53)
NO167295C (no) Fremgangsmaate for fremstilling av et terapeutisk aktivt peptid.
DK0475394T3 (da) Rotte C-type natriuretisk peptid cDNA, og precursorprotein
ATE241011T1 (de) Serin-reiche peptidlinker
DK0794961T3 (da) LHRH-antagonistpeptider
SE8605189L (sv) Nya kalcitoninderivat
NO971621D0 (no) Keratinocyttvekstfaktoranaloger
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
SE9603468D0 (sv) New compounds
SE7712634L (sv) Ny polypeptid med serumkalciumreducerande aktivitet
DK0490383T3 (da) Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
AU2254588A (en) Biologically active segments of several growth hormones
SE9603461D0 (sv) New compounds
DE69126150D1 (de) Heparin bindender Wachstumsfaktor
SE9603463D0 (sv) New compounds
SE9603462D0 (sv) New compounds
DK53290A (da) Syntetiske gaer-leader-peptider
EP0266006A3 (de) Blutdrucksenkende, diuretische Peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee